Unlocking aspirin's chemopreventive activity: Role of irreversibly inhibiting platelet cyclooxygenase-1

Cancer Prevention Research

Volumn 10, Issue 2, 2017, Pages 142-152

  Lichtenberger, Lenard M ^a   Fang, Dexing ^a   Bick, Roger J ^b   Poindexter, Brian J ^b   Phan, Tri ^a   Bergeron, Angela L ^c   Pradhan, Subhashree ^c   Dial, Elizabeth J ^a   Vijayan, K Vinod ^c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA CATENIN; CYCLOOXYGENASE 1; FIBRONECTIN; HEMOGLOBIN; THROMBOXANE; TRANSCRIPTION FACTOR SNAIL; VASCULOTROPIN; VIMENTIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CELL STRUCTURE; CHEMOPROPHYLAXIS; COLON CANCER; COLON CELL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FECES LEVEL; GASTROINTESTINAL HEMORRHAGE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; THROMBOCYTE ACTIVATION; TUMOR INVASION; ANIMAL; BAGG ALBINO MOUSE; COLON TUMOR; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOLOGY; THROMBOCYTE; TUMOR CELL LINE;

ANIMALS; ASPIRIN; BLOOD PLATELETS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MICE; MICE, INBRED BALB C; PLATELET ACTIVATION;

EID: 85011965806     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-16-0241     Document Type: Article

References (49)

1. Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 2015;26:47-57.
2. Vane J. Towards a better aspirin. Nature 1994;367:215-6.
3. Vane JR. Nobel lecture. Adventures and excursions in bioassay-The stepping stones to prostacyclin. Postgrad Med J 1983;59:743-58.
4. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002;3:425-30.
5. Levin J, Conley CL. Thrombocytosis associated with malignant disease. Arch Intern Med 1964;114:497-500.
6. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007;110:1723-9.
7. Mitrugno A, Tormoen GW, Kuhn P, McCarty OJ. The prothrombotic activity of cancer cells in the circulation. Blood Rev 2016;30:11-9.
8. Salgado R, Benoy I, Bogers J, Weytjens R, Vermeulen P, Dirix L, et al. Platelets and vascular endothelial growth factor (VEGF): A morphological and functional study. Angiogenesis 2001;4:37-43.
9. Kirwan CC, Byrne GJ, Kumar S, McDowell G. Platelet release of vascular endothelial growth factor (VEGF) in patients undergoing chemotherapy for breast cancer. J Angiogenes Res 2009;1:7.
10. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011;20:576-90.
11. Rothwell PM, Fowkes FG, Belch JF, OgawaH, Warlow CP, Meade TW. Effect of daily aspirin on long-Term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet 2011;377:31-41.
12. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet 2012;379:1591-601.
13. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-58.
14. Trabert B, Ness RB, Lo-CiganicWH, Murphy MA, Goode EL, Poole EM, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: A pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 2014;106:djt431.
15. Sahasrabuddhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, Park Y, et al. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst 2012;104:1808-14.
16. Van Dyke AL, Cote ML, Prysak G, Claeys GB, Wenzlaff AS, Schwartz AG. Regular adult aspirin use decreases the risk of non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev 2008;17:148-57.
17. Fraser DM, Sullivan FM, Thompson AM, McCowan C. Aspirin use and survival after the diagnosis of breast cancer: A population-based cohort study. Br J Cancer 2014;111:623-7.
18. Sclabas GM, Uwagawa T, Schmidt C, Hess KR, Evans DB, Abbruzzese JL, et al. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 2005;103:2485-90.
19. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 2012;30:3540-4.
20. Gamba CA, Swetter SM, Stefanick ML, Kubo J, Desai M, Spaunhurst KM, et al. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: The Women's Health Initiative. Cancer 2013;119:1562-9.
21. Lichtenberger LM, Romero JJ, de Ruijter WM, Behbod F, Darling R, Ashraf AQ, et al. Phosphatidylcholine association increases the anti-inflammatory and analgesic activity of ibuprofen in acute and chronic rodent models of joint inflammation: relationship to alterations in bioavailability and cyclooxygenase-inhibitory potency. J Pharmacol Exp Ther 2001;298: 279-87.
22. Lichtenberger LM, Romero JJ, Dial EJ. Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. Br J Pharmacol 2007;150:913-9.
23. Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, Marathi UK. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: A randomized clinical trial. Am J Gastroenterol 2011; 106:272-7.
24. Bibbins-Domingo K, U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2016;164:836-45.
25. Bynagari YS, Nagy B Jr, Tuluc F, Bhavaraju K, Kim S, Vijayan KV, et al. Mechanism of activation and functional role of protein kinase Ceta in human platelets. J Biol Chem 2009;284:13413-21.
26. Khatlani T, Pradhan S, Da Q, Gushiken FC, Bergeron AL, Langlois KW, et al. The beta isoform of the catalytic subunit of protein phosphatase 2B restrains platelet function by suppressing outside-in alphaII b beta3 integrin signaling. J Thromb Haemost 2014;12:2089-101.
27. Dial EJ, Doyen JR, Lichtenberger LM. Phosphatidylcholine-Associated nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit DNA synthesis and the growth of colon cancer cells in vitro. Cancer Chemother Pharmacol 2006;57:295-300.
28. Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, et al. Platelets increase the proliferation of ovarian cancer cells. Blood 2012;120:4869-72.
29. Clapper ML, Cooper HS, Chang WC. Dextran sulfate sodium-induced colitis-Associated neoplasia: A promising model for the development of chemopreventive interventions. Acta Pharmacol Sin 2007;28:1450-9.
30. Wargovich MJ, Jimenez A, McKee K, Steele VE, Velasco M, Woods J, et al. Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis 2000;21:1149-55.
31. Qi C, Li B, Guo S, Wei B, Shao C, Li J, et al. P-selectin-mediated adhesion between platelets and tumor cells promotes intestinal tumorigenesis in Apc (Min/) mice. Int J Biol Sci 2015;11:679-87.
32. Miyashita T, Tajima H, Makino I, Nakagawara H, Kitagawa H, Fushida S, et al. Metastasis-promoting role of extravasated platelet activation in tumor. J Surg Res 2015;193:289-94.
33. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012;9:259-67.
34. Cha YI, Du Bois RN. NSAIDs and cancer prevention: Targets downstream of COX-2. Annu Rev Med 2007;58:239-52.
35. Roelofs HM, Te Morsche RH, van Heumen BW, Nagengast FM, Peters WH. Over-expression of COX-2 mRNA in colorectal cancer. BMC Gastroenterol 2014;14:1.
36. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342: 1946-52.
37. Movahedi M, Bishop DT, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: A prospective investigation in the CAPP2 study. J Clin Oncol 2015;33:3591-7.
38. Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, Laurberg S, Laiho P, Aaltonen LA, et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 2005;54:374-84.
39. Voelker M, Hammer M. Dissolution and pharmacokinetics of a novel micronized aspirin formulation. Inflammopharmacology 2012;20: 225-31.
40. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1993;90:11693-7.
41. Bruno A, Dovizio M, Tacconelli S, Patrignani P. Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2012;26:e1-e13.
42. Lichtenberger LM. The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol 1995;57:565-83.
43. Lichtenberger LM, Wang ZM, Romero JJ, Ulloa C, Perez JC, Giraud MN, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1995;1:154-8.
44. Lichtenberger LM, Barron M, Marathi U. Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity. Drugs Today 2009;45:877-90.
45. Corpet DE, Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-Analysis of colon chemoprevention in rats, mice and men. Eur J Cancer 2005; 41:1911-22.
46. Mori M, Salter JW, Vowinkel T, Krieglstein CF, Stokes KY, Granger DN. Molecular determinants of the prothrombogenic phenotype assumed by inflamed colonic venules. Am J Physiol Gastrointest Liver Physiol 2005; 288:920-6.
47. Guillem-Llobat P, Dovizio M, Bruno A, Ricciotti E, Cufino V, Sacco A, et al. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget 2016;7:32462-77.
48. Alfonso L, AiG, Spitale RC, Bhat GJ. Molecular targets of aspirin and cancer prevention. Br J Cancer 2014;111:61-7.
49. Usman MW, Luo F, Cheng H, Zhao JJ, Liu P. Chemopreventive effects of aspirin at a glance. Biochim Biophys Acta 2015;1855:254-63.